The effectiveness of electroneuromyography in the early diagnosis of diabetic foot development

Yıl 2021, Cilt: 4 Sayı: 2, 213 - 218, 28.03.2021

Fatma Kesmez Can , Nuray Bilge , Handan Alay , Mehmet Parlak

https://doi.org/10.32322/jhsm.856117

Öz

Objective: Diabetic foot is one of the first cause of lower extremity amputation. The aim of this study is to determine which of the nerve conduction disorders may be used predominantly for early diagnosis of diabetic foot development in the follow-up of diabetic patients.
Material and Method: The study consists of 3 different groups (150) of patients diagnosed with type 2 diabetes (DM). 1. Group; 50 patients with diabetic foot complications (DA+), 2. Group; 50 patients without diabetic foot complications and with polyneuropathy (DA-/PNP+), 3. Group; 50 patients without diabetic foot complications and without polyneuropathy (DA-/PNP-). Diabetic foot wounds were grouped by pedis classification.
Findings: Age, sex, diabetes duration, blood glucose, HbA1c values and electroneuromyography (ENMG) for nerve amplitude, velocity and latancy results were compared among the groups. A significant statistical difference was found between three groups when age, sex, HgbA1c, fasting blood glucose, diabetes duration were evaluated (p<0.05). All DA+ patients had PNP+. In the DA+ group, unlike DA-/PNP+ group, the motor nerves of the lower extremities were also involved. Tibial nerve velocity was lower than normal in DA+ patients and normal in other groups (p<0.05). A statistically significant difference was found in peroneal nerve conduction velocity between the DA+ group and the DA- groups (p<0.05). Peroneal nerve conduction velocity was not statistically significant between DA-/PNP+ and DA-/PNP- groups (p>0.05). Peroneal nerve conduction velocity was lowest in the DA+ group. This factor was considered as a risk factor for DA development.
Conclusions: In conclusion, the slowdown in peroneal nerve conduction velocity and the increase in diabetes duration were the primary risk factors for diabetic foot development, and the decrease in tibial nerve velocity was also considered as significant. This study showed that the involvement of motor nerve conduction in the lower extremity was considered as a signal for diabetic foot development.

Anahtar Kelimeler

Diabetic foot, Polyneuropathy, ENMG

Kaynakça

• Monteiro-Soares M, Boyko EJ, Ribeiro J, Ribeiro I, Dinis-Ribeiro M. Predictive factors for diabetic foot ulceration: a systematic review. Diabetes Metab Res Rev 2012; 28: 574-600.
• Zhang P, Lu J, Jing Y, Tang S, Zhu D, Bi Y. Global epidemiology of diabetic foot ulceration: a systematic review and meta -analysis. Ann Med 2017; 49: 106-16.
• American Diabetes Association Diabetes Care, Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes Diabetes Care 2019; 42: 124-38.
• Schaper NC. Diabetic foot ulcer classification system for research purposes: a progress report on criteria for including patients in research studies. Diabetes Metab Res Rev 2004; 20: 90-5.
• Vileikyte L, Leventhal H, Gonzalez JS, et al. Diabetic peripheral neuropathy and depressive symptoms. Diabetes Care 2005; 28: 2378-83.
• Pop-Busui R, Boulton AJM, Feldman EL, Diabetic Neuropathy: A Position Statement by the American Diabetes Association. Diabetes Care 2017; 40: 136-54.
• Gregg EW, Gu Q, Williams D, Prevalence of lower extremity diseases associated with normal glucose levels, impaired fasting glucose, and diabetes among U.S. adults aged 40 or older. Diabetes Res Clin Pract 2007; 77: 485–88.
• Boulton AJM, Vinik AI, Arezzo JC, et al. Diabetic Neuropathies. Diabetes Care 2005; 28: 956-62.
• Smith BE, Chapter 3 Focal and entrapment neuropathies, Handbook of Clinical Neurology 2014; 126: 31-43.
• Weiss L, Silver JK, Weiss J. Easy EMG. Elsevier, 15th April 2015, Page Count: 296.
• Ahmad J, The diabetic foot, Diabetes Metab Syndr 2016; 10: 48-60.
• Mottaghi T, Khorvash F, Maracy M, Bellissimo N, Askari G. Effect of folic acid supplementation on nerve conduction velocity in diabetic polyneuropathy patients, Neurol Res 2019; 41: 364-68.
• Abboud RJ, Rowley DI, Newton RW. Lower limb muscle dysfunction may contribute to foot ulceration in diabetic patients. Clin Biomech 2000; 15: 37-45.
• Karsidag S, Moralı S, Sargın M, Salman S, Karsidag K, Us O. The electrophysiological findings of subclinical neuropathy in patients with recently diagnosed type 1 diabetes mellitus. Diabetes Res Clin Pract 2005; 67: 211–9.
• Kakrani AL, Gokhale VS, Vohra KV, Chaudhary N. Clinical and nerve conduction study correlation in patients of diabetic neuropathy. J Assoc Physicians India 2014; 62: 24-7.
• Kiziltan ME, Gunduz A, Kiziltan G, Akalin MA, Uzun N. Peripheral neuropathy in patients with diabetic foot ulcers: clinical and nerve conduction study. J Neurol Sci 2007; 15: 75-9.
• Kulkarni AP, Saroja AO, Naik KR, Ghatnatti V, Hesarur N. Nerve conduction abnormalities in patients with newly diagnosed diabetes mellitus. J Sci Soc 2018; 45: 30-3.
• Taşkıran B, Güldiken S, Turgut N, Güldiken B, Tuğrul A. Electrophysiological risk factor in the development of diabetic foot: pobterior tibial nerve conduction pathology. Yeni Symp. 2009; 47: 76-9.
• Singh N, Armstrong DG, Lipsky BA. Preventing foot ulcers in patients with diabetes. JAMA 2005; 12: 217-28.
• Zelen CM, Serena TE, Snyder RJ. A prospective, randomised comparative study of weekly versus biweekly application of dehydrated human amnion/chorion membrane allograft in the management of diabetic foot ulcers. Int Wound J 2014; 11: 122-8.